Therapeutics vs diagnostics seed VCs: ticket size and fit 2026

The two buckets of therapeutics diagnostics seed VCs split on ticket size and fund archetype. Rx seeds run larger with dedicated life-science funds; Dx seeds run smaller with digital-health and platform funds; a small crossover set writes both. Match milestones to the bucket before you build the target list.

Most founders pitch "bio seed" funds as one list. That is the mistake. Therapeutics and diagnostics seed VCs back different companies at different sizes on different timelines, and the founders who get term sheets build two separate target lists and pitch each with subsector-specific milestones.

The structural split is sharp. Rx seeds are larger, run on a multi-year path to a therapeutic milestone, and concentrate in dedicated life-science and platform funds. Dx seeds are smaller, run on a shorter path to revenue or a regulatory gate, and mix digital-health, health-tech, and platform funds. Only a small crossover set writes both.

What separates therapeutics from diagnostics seed VCs?

Therapeutics seed VCs fund drug programs heading toward IND-enabling studies and carry multi-round reserve capital for long clinical timelines. Diagnostics seed VCs fund assays or devices heading toward a CLIA waiver, 510(k) clearance, or commercial launch on a shorter capital path. Different milestones, different check sizes, largely different fund lists.

Don't assume one target list covers both. Separate them from the first outreach.

The ticket size gap in Rx vs Dx fundraising

Diagnostics seed fundraising clears digital-health check sizes; therapeutics seeds clear life-science check sizes. That one split reshapes your target list before you write a single email.

The cleanest public proxy for Dx seed sizing is digital-health deal data. CB Insights reported the median digital health deal size rose to $5.3M in 2024, a 39% year-over-year increase on lower deal counts. On the Rx side, the PitchBook-NVCA Venture Monitor documented median life-sciences valuations reaching record levels through 2025, a flight to quality that concentrates larger checks in top biotech seeds.

Do map your capital ask to the archetype above before any outreach. Don't pitch a $10M Rx seed to a digital-health fund; the check size and reserve model do not line up.

Milestones VCs expect from a dx startup seed

For a dx startup seed, the assay is the milestone. Everything else is supporting evidence.

• Analytical sensitivity and specificity: Benchmarked numbers on intended sample types. Contrived-sample data carries less weight in diligence.
• Sample volume processed: Enough real-sample runs on enough collection sites to trust the performance claim, not a small one-site pilot.
• Regulatory plan: CLIA waiver timeline, 510(k) predicate, or LDT compliance path. The FDA's 2024 LDT Final Rule requires many IVDs offered as LDTs to meet medical device premarket requirements starting in May 2025, making the regulatory answer a seed-stage diligence item, not a Series B one.
• Clinical credibility on the team: A co-founder or advisor with prior FDA clearances is a diligence shortcut; the team has run the gauntlet before.

Don't pad the deck with in silico data when the VC expects wet-lab sample runs.

What a therapeutics seed VC pitch must prove

A therapeutics seed VC pitch sells a target-validation package and a plausible path to IND, not a hypothesis.

• Target and modality rationale: Why this target, why this modality, why now. Disease biology reasoning has to hold up in diligence; weak biology kills the deal.
• Lead series with preliminary data: Hit rates, early SAR, selectivity against obvious off-targets. Animal efficacy carries more weight than cellular data alone.
• IND path and cost: A line-of-sight preclinical package with a credible burn number through IND. Scope the round to the distance to the next value inflection, not to the current data.
• Team and platform reuse: The chemistry or biology should stand up beyond a single program. Platform reuse compounds the bet beyond one asset.

The First Round position on seed-stage diligence applies here: seed VCs weigh team, traction, and market over long-horizon clinical data. The clinical story compounds later; the team and target call must be defensible at the seed.

Don't sell a target hypothesis without a lead series; it dies in diligence.

Crossover funds in the bio seed subsector

Three fund archetypes genuinely write both Rx and Dx seed checks in the bio seed subsector. They price on a different reference class from pure-play shops, so identify them early.

• Company-creation platform funds: Spin out Rx and Dx from the same scientific platform. Pitch these on platform reuse first, individual program second.
• Multi-stage life-science funds with a seed program: Their diligence bar runs higher, but they carry later-stage reserves, which matters more for Rx than Dx.
• Large generalist funds with a bio team: Health-first generalists that touch both digital health and life sciences. Treat these as follow-on conviction, not the lead candidate for a pure Rx seed.

Do map every fund on your list to one of these three archetypes. Don't treat them as interchangeable; the diligence style differs materially.

If your outbound list runs over 20 funds, tools like Causo handle subsector-specific personalization and routing.

FAQ

Are diagnostics seed rounds smaller than therapeutics seed rounds?

Yes. Diagnostics seeds typically come in at a fraction of a therapeutics round because the capital needed to reach a CLIA-validated assay is lower than the capital needed to reach IND-enabling studies. CB Insights put the median digital health deal at $5.3M in 2024, the closest public proxy for Dx seed sizing.

Which venture capital firms invest most in diagnostics seed rounds?

Diagnostics is dominated by digital-health funds and platform-bio funds rather than dedicated Dx shops. Build a target list across generalist health-tech funds, the life-sciences arms of platform funds, and the small number of Dx-first seed funds. Crossover funds that also do therapeutics are a third bucket worth targeting.

What milestones do VCs expect for a diagnostics seed round?

Seed VCs want a working assay with benchmarked analytical sensitivity and specificity, a proof-of-concept sample run on intended sample types, and a credible regulatory path (CLIA waiver or 510(k) plan). First Round notes seed investors weigh team, traction, and market over deep clinical data.

How much does a therapeutics seed round typically raise in 2024–2025?

Therapeutics seeds are structurally larger than diagnostics seeds because preclinical and IND-enabling work is capital intensive. PitchBook-NVCA reported life-sciences median valuations rose through 2025 alongside larger check sizes for top biotech seeds. The trend applies most cleanly to top-quartile biotech seeds, which set the reference class for Rx-specialist pricing.

Which VCs write both diagnostics and therapeutics checks?

A small set of platform funds write both. They are usually company-creation shops spinning out Rx and Dx from one scientific platform, multi-stage life-sciences funds with a seed program, or large generalists with a bio team who co-lead Dx and lead Rx only inside their core thesis.